GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
-4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| 1 |
Philip Morris
PM
|
$43M |
| 2 |
Amazon
AMZN
|
$24.3M |
| 3 |
Palantir
PLTR
|
$16.8M |
| 4 |
Yum China
YUMC
|
$14.4M |
| 5 |
Hims & Hers Health
HIMS
|
$10.9M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$40.6M |
| 2 |
NVIDIA
NVDA
|
$25.7M |
| 3 |
KE Holdings
BEKE
|
$14.3M |
| 4 |
Meta Platforms (Facebook)
META
|
$13.3M |
| 5 |
Coca-Cola
KO
|
$9.83M |
Sector Composition
| 1 | Technology | 42.51% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 7.8% |
| 5 | Consumer Staples | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
551
Theravance Biopharma
TBPH
$714M
| $11.2K | ﹤0.01% |
1,258
+225
| +22% | +$2.01K |
|
552
Relay Therapeutics
RLAY
$697M
| $11.2K | ﹤0.01% |
4,286
+771
| +22% | +$2.02K |
|
553
Phibro Animal Health
PAHC
$1.59B
| $11.1K | ﹤0.01% |
520
+93
| +22% | +$1.99K |
|
|
INN
554
Summit Hotel Properties
INN
$630M
| $11K | ﹤0.01% |
2,033
+80
| +4% | +$433 |
|
555
MindMed
MNMD
$693M
| $11K | ﹤0.01% |
1,877
+337
| +22% | +$1.97K |
|
556
Phathom Pharmaceuticals
PHAT
$879M
| $11K | ﹤0.01% |
1,751
+315
| +22% | +$1.98K |
|
557
Precigen
PGEN
$1.37B
| $10.8K | ﹤0.01% |
+7,259
| New | +$10.8K |
|
558
Keros Therapeutics
KROS
$641M
| $10.6K | ﹤0.01% |
1,036
+192
| +23% | +$1.96K |
|
|
GMRE
559
Global Medical REIT
GMRE
$508M
| $10.5K | ﹤0.01% |
1,202
+78
| +7% | +$683 |
|
560
Zevra Therapeutics
ZVRA
$497M
| $10.2K | ﹤0.01% |
1,367
+246
| +22% | +$1.84K |
|
|
MESO
561
Mesoblast
MESO
$1.84B
| $10.2K | ﹤0.01% |
817
+146
| +22% | +$1.82K |
|
|
UHT
562
Universal Health Realty Income Trust
UHT
$571M
| $10.1K | ﹤0.01% |
247
+10
| +4% | +$410 |
|
563
Oric Pharmaceuticals
ORIC
$1.07B
| $10.1K | ﹤0.01% |
1,807
+325
| +22% | +$1.81K |
|
564
SIGA Technologies
SIGA
$606M
| $10K | ﹤0.01% |
1,828
+329
| +22% | +$1.8K |
|
565
Tourmaline Bio
TRML
$668M
| $9.98K | ﹤0.01% |
656
+118
| +22% | +$1.8K |
|
566
Erasca
ERAS
$434M
| $9.92K | ﹤0.01% |
7,240
+1,304
| +22% | +$1.79K |
|
|
VERV
567
DELISTED
Verve Therapeutics
VERV
| $9.9K | ﹤0.01% |
2,167
+389
| +22% | +$1.78K |
|
568
Sana Biotechnology
SANA
$746M
| $9.6K | ﹤0.01% |
5,716
+1,028
| +22% | +$1.73K |
|
569
CorMedix
CRMD
$938M
| $9.57K | ﹤0.01% |
1,554
+280
| +22% | +$1.73K |
|
|
CHCT
570
Community Healthcare Trust
CHCT
$447M
| $9.57K | ﹤0.01% |
527
+21
| +4% | +$381 |
|
|
FPI
571
Farmland Partners
FPI
$479M
| $9.57K | ﹤0.01% |
858
+33
| +4% | +$368 |
|
|
BCYC
572
Bicycle Therapeutics
BCYC
$493M
| $9.56K | ﹤0.01% |
1,126
+202
| +22% | +$1.72K |
|
573
EyePoint Pharmaceuticals
EYPT
$859M
| $9.47K | ﹤0.01% |
1,747
+314
| +22% | +$1.7K |
|
|
RAPP
574
Rapport Therapeutics
RAPP
$571M
| $9.39K | ﹤0.01% |
936
+168
| +22% | +$1.69K |
|
|
ALX
575
Alexander's
ALX
$1.2B
| $9.2K | ﹤0.01% |
44
+3
| +7% | +$627 |
|